



A springboard for Natural products?

Chris Molloy, CEO



Declarations of genuine interest

- Past
 - 5 years developing COPD compounds from a natural product warhead in **pharma**
 - 4 years in a leading NP **biotech**
- Present
 - Developed synthetic compounds for HIV based upon NP tools
- Future
 - ‘Undruggable’ targets need new style warheads
 - Polypharmacy (multiple warheads)
 - New synthesis and analysis methods to overcome the hurdles



We are:

**Biotech · Pharma ·
Academia · CROs ·
Charities · Finance**

**Scope = Target
validation to Phase 2**

**‘Small molecules’
then biologics**

- Supporting innovative ‘Fast-to-Patient’ Medicines Discovery
- Building a dynamic platform for applied, community R&D to help you address systemic problems
- Targeting shared problems which no single stakeholder group can convene or complete by themselves
- Fostering the wealth and health of the UK community alongside the Catalyst
- Doing wet science, informatics, virtual discovery, technology development, process challenge

With a Board who understand the value-chain



Professor Graham Boulnois (chair)
Biotech VC investor, pharma executive
and academic



Dr Clive Dix
Biotech entrepreneur and pharma exec
with more than 30 years in research
and commercial roles



Professor Sir Alex Markham
Professor of Medicine and Director of the
MRC Medical Bioinformatics Centre at
the University of Leeds



Professor Clive Morris
Professor of Translational Medicine at
the University of Manchester and a
Director and investment committee
member of Wheatsheaf Investments
Ltd



Professor Carole Longson
Director of the Centre for Health
Technology Evaluation and an
Executive Director at NICE



Peter Kellner
Former YouGov President and Chair, a
journalist, political analyst and public
health activist



Chris Reilly
Formerly Global Vice President and Head
of Project Evaluation at AstraZeneca, an
expert in the discovery and early clinical
development of new medicines



Kate Bellingham
Leading engineer and a fellow of the
Women's Engineering Society, a
Patron of WISE and an active
volunteer STEM Ambassador

... and sector experts on our team



Mark Samuels
MD NIHR
Clinical
Research
Infrastructure



Dr Richard Seabrook
Director of BD,
Wellcome Trust



Ed Owen
Former CEO, CF
Trust and Govt
advisor

MEDICINES DISCOVERY CATAPULT MAKES FOUR SENIOR HIRES TO MANAGEMENT TEAM


Four more leading figures from the life sciences sector have joined the Medicines Discovery Catapult to complete the Senior Management line-up.

John Overington (CIO), Marcus Harrison (COO), Mark Samuels (CBSO) and Peter Simpson (CSO), join CEO Chris Molloy, as work begins in earnest on a

Dr John Overington, Chief
Information Officer

Dr Marcus Harrison, Chief
Operating Officer

Dr Peter Simpson, Chief Scientific
Officer



Don't forget these guys


Consultants, VC Angels, IP & Legal, Patients

Our Objectives

Raise the tide for UK Medicines R&D by

- Catalysing **collaborative R&D** in areas of shared community need
- Helping **Concept Validation** : making assets financeable
- Translating academic models into the industrial community
- **Reducing the friction** in the flow of information through Medicines Discovery
- Providing SMEs with access to scarce assets and capability
- Proving a national workbench for ideas that can supply pharma with assets

Removing the bubbles




Barriers : the Grand National of NPs


- **Just too complex**
- **Just too big**
 - ‘we need things that can be formulated easily’
- **Just too costly**
 - ‘we need things we can manufacture’
- **Just too variable**
 - ‘we don’t want a crop, we want a process’
- **Just too last century**
 - ‘we have found all the good compounds’
- **Just too late**
 - ‘no-one in our network knows about how to use them’ ‘we want a simple non-chiral, compound’



Capabilities to bring the community together




A turbo for collaborative technology development



Enables technology and tool development across the value chain

Helps partners de-risk their assets


A model for putting patients first



We anchor
ourselves to the
ground through
projects with
impact



Open for business: what we're already engaged with within our first 6 months



Initial Therapeutic Areas : **AMR; Inflammation ; CNS**

Glimmers of light




© Luke Harvey

rights reserved.

Glimmers of light

- Undruggable or just undrugged?
- New methods of manufacture
- New methods of analysis
- New companies
- Can we save the skills in time?



A moonshot for chemistry

Proposal to automate the synthesis of natural product molecules could be a boon for drug discovery



Example : Analytics and AMR@Warwick

In vitro Assays and Analytical
techniques for discovery:
Impact of Solid State NMR

- Addresses assay development and prosecution of multimeric drug targets, starting in AMR
- **Provides first ever community access to solid state NMR and skills**
- Enables collaborations with technology SMEs, anti-infectives SMEs, novel chemistry providers and CROs with interest in NMR

Latest news



CATAPULT OPEN FOR BUSINESS WITH £1M INVESTMENT IN CUTTING- EDGE LAB CAPACITY TO SUPPORT UK DRUG DISCOVERY

World-class technology and expertise are now available to UK drug discovery companies as a result of new laboratory facilities developed by the Medicines

The R&D environment is crowded

We will therefore

- target the gaps
- collaborate and communicate intensively
- not compete with our community

Benefits

- Joined up solutions built for the community, not only single sectors
- Assets and technologies distributed to the community early
- Wealth, and health




Is this your view of the world?



Take homes for NPs

- Biochemistry remains a 'natural' source of bioactive chemistry, not yet fully exploited
- MDC are a collaborative R&D platform for the community to address technology, concept and process barriers



Medicines Discovery Catapult

Mereside, Alderley Park,
Alderley Edge, Cheshire,
SK10 4TG

md.catapult.org.uk

@MediDiscCat

info@md.catapult.org.uk

CATAPULT
Medicines Discovery

